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A cardinal feature of systemic lupus erythematosus (SLE) is the development of autoantibodies. 
The first autoantibodies described in patients with SLE were those specific for nuclei and 
DNA, but subsequent work has shown that individuals with this disease produce a panoply of 
different autoantibodies. Thus, one of the constant features of SLE is a profound breakdown 
in tolerance in the antibody system. The appearance of self-reactive antibodies in SLE 
precedes clinical disease, but where in the B cell pathway tolerance is first broken has not 
been defined. In healthy humans, autoantibodies are removed from the B cell repertoire in 
two discrete early checkpoints in B cell development. We found these checkpoints to be 
defective in three adolescent patients with SLE. 25–50% of the mature naive B cells in SLE 
patients produce self-reactive antibodies even before they participate in immune responses 
as compared with 5–20% in controls. We conclude that SLE is associated with abnormal 
early B cell tolerance.
 
Systemic lupus erythematosus (SLE) is a multi-
gene autoimmune disorder characterized by a
constellation of clinical abnormalities (1–3) that
can affect nearly all of the components of the
immune system (4–8). However, a hallmark of
SLE is the production of autoantibodies that
are involved in pathogenic immune complex
formation and deposit in the kidneys of pa-
tients (9). The first autoantibodies described in
patients with SLE were those specific for nuclei
and DNA (10), but subsequent work has
shown that individuals with this disease produce
a diverse group of autoantibodies (9, 11), pre-
dominantly somatically mutated, class-switched
IgGs. These antibodies are produced by antigen-
experienced B cells, implicating abnormalities
in tolerance in late stage B cells, but it has not
been determined where B cell tolerance is first
broken in SLE (12).
In healthy individuals, B cells that express
autoreactive antibodies including antinuclear
antibodies (ANAs) and polyreactive antibodies
represent 55–75% of the highly diverse reper-
toire that is constantly generated by random Ig
gene rearrangement during early B cell devel-
opment in the BM. To ensure self-tolerance,
autoreactive B cells producing such potentially
harmful antibodies are efficiently removed
from the naive repertoire at two checkpoints
(13). The first checkpoint is at the immature B
cell stage in the BM where the majority of
polyreactive and ANAs are lost. The second
checkpoint is in the periphery before maturation
of new emigrant B cells into naive immuno-
competent lymphocytes. Three mechanisms
have been described to silence developing au-
toreactive B cells at the first checkpoint for
self-tolerance in the bone marrow: deletion,
anergy, and receptor editing (14–17). How
tolerance is established at the second check-
point in the periphery is less clear, and both
positive and negative selection mechanisms
have been proposed (18–23). Although the
mechanisms that silence autoreactive B cells at
the two checkpoints might be very different,
failure to remove autoantibodies at either stage
would likely result in increased numbers of naive
circulating self-reactive B cells in the periphery
and, therefore, potentially increased suscepti-
bility to autoimmunity.
Here, we show that SLE is associated with
a failure to establish self-tolerance during early
B cell development leading to increased num-
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bers of autoreactive mature naive B cells circulating in pe-
ripheral blood of untreated patients.
 
RESULTS
Antibody cloning from single purified new emigrant 
and mature naive B cells of patients with SLE
 
To examine early B cell tolerance checkpoints in patients
with SLE, we cloned, expressed, and tested the reactivity of
222 antibodies from single B cells derived from peripheral
blood of three untreated adolescent SLE patients (Supple-
mental Materials and methods, available at http://www.jem.
org/cgi/content/full/jem.20042251/DC1). All three SLE
patients were diagnosed based on the Revised Criteria of the
American College of Rheumatology and their clinical diag-
nostic features reflected the heterogeneity of this systemic
autoimmune disease (Table I, reference 24, and Supplemen-
tal Materials and methods).
Antibodies were cloned from cDNA libraries created
from single cells purified from newly emigrated (CD19
 
 
 
CD10
 
 
 
IgM
 
 
 
CD27
 
 
 
) and mature naive B cell (CD19
 
 
 
CD10
 
 
 
IgM
 
 
 
CD27
 
 
 
) compartments (references 13, 25–27
and Tables S1–S6 and Fig. S1, available at http://www.jem.
org/cgi/content/full/jem.20042251/DC1). The sorted cells
lacked CD27, a memory B cell marker, and the cloned anti-
bodies were not somatically mutated or clonally related as
determined by sequence analysis (references 26, 27 and Ta-
bles S1–S6). Therefore, these B cells were naive and showed
no evidence of having been highly clonally expanded during
their development.
 
Ig gene usage abnormalities are not consistent among 
patients with SLE
 
Abnormalities in Ig gene usage have been observed in SLE
patients, and there is no evidence for changes in the reper-
toire between adolescents and adults (28–38). Therefore, we
compared the Ig gene repertoire and Ig heavy (IgH) chain
characteristics such as CDR3 length and positive charges,
which have been associated with autoreactivity, between
new emigrant and mature naive B cells from SLE patients
and our previously published healthy controls (Fig. 1 and
reference 13). Although our study is limited to three pa-
tients, we found that they displayed many of the antibody
sequence abnormalities reported by others (Fig. 1 and refer-
ences 28–38). For example, mature naive B cells from
SLE122 showed a decrease in V
 
H
 
4 (10.4 vs. 30.4% in con-
trols) and increased V
 
H
 
3 (60.4 vs. 39.3% in controls) gene
family representation (Fig. 1 B). SLE122 was also unusual in
that IgH chains from both new emigrant and mature naive B
cells displayed short CDR3 regions (Fig. 1, A and B). In this
patient, the average IgH CDR3 length was 12.6 amino acids
(aa) in new emigrant B cells compared with 14.1 aa in con-
trols (P 
 
 
 
 0.033) and 11.5 aa in mature naive B cells com-
pared with 13.4 aa in controls (P 
 
 
 
 0.003). We found no
evidence for an increase in Ig light (IgL) chain receptor edit-
ing as determined by downstream J
 
 
 
/
 
 
 
 usage, but V
 
 
 
4-1
was overrepresented in SLE100 and SLE122 (Fig. 1, C and
D, and references 28, 35). Despite these alterations in the Ig
gene usage in individual patients, we found no consistent Ig
gene repertoire or sequence abnormalities in the antibodies
expressed by new emigrant and mature naive B cells from
patients with SLE (Fig. 1 and Tables S1–S6).
 
Autoreactive antibodies fail to be removed at the transition 
between new emigrant and mature naive B cells 
in patients with SLE
 
To determine the frequency of autoreactive antibodies in
new emigrant and mature naive B cells in SLE, we expressed
antibodies cloned from single cells and tested them for au-
toreactivity by HEp-2 cell lysate ELISA and indirect immu-
nofluorescence assay (IFA) on fixed HEp-2 cells (Fig. 2,
Fig. S2, available at http://www.jem.org/cgi/content/full/
jem.20042251/DC1, and Tables S1–S6). The HEp-2 ELISA
assay is a clinical test for ANA reactivity that uses HEp-2 cell
lysate as the antigen (Fig. 2, A and B). Using this assay, we
reported previously that 40.7% of new emigrant and 20.4%
of mature naive B cells from healthy individuals express
HEp-2–reactive antibodies (Fig. 2 and reference 13). Thus,
healthy humans display a checkpoint in B cell development
between the new emigrant and mature naive compartments
that removes a substantial number of HEp-2–reactive anti-
bodies (13). Antibodies from new emigrant B cells from SLE
patients were not significantly different in HEp-2 ANA
ELISA reactivity (40.7% in controls and 40.5–59.4% in SLE;
P 
 
  
 
0.401) from antibodies of healthy donors (Fig. 2 A and
reference 13). In contrast, antibodies from mature naive B
cells from all three SLE patients differed from controls in that
they retained high levels of HEp-2 ANA ELISA–reactive
antibodies (41.5–50.0 compared with 20.4% in controls,
P 
 
  
 
0.0003; P 
 
 
 
 0.009 for SLE100, P 
 
 
 
 0.004 for SLE101,
and P 
 
 
 
 0.031 for SLE122; Fig. 2 B and reference 13). We
conclude that mature naive B cells in these three adolescent
SLE patients are enriched in antibodies that react with HEp-2
cell lysates.
High affinity ANAs are a hallmark of SLE. To deter-
mine if HEp-2 ELISA–reactive antibodies from B cells of
 
Table I.
 
Patient characteristics
 
SLE100 SLE101 SLE122
 
Gender F M F
Age at diagnosis (yr) 15 15 9
Clinical features arthritis myocarditis chorea
Lupus nephritis IIB III IIB
Hematology L, A, T A L, A
Serology D, P, Sm, RNP P D
ANA
 
    
 
C3/C4 low low low
Treatment none none none
Family history maternal SLE maternal IDDM, 
paternal MS
none
 
A, anemia; D, anti-dsDNA antibody; L, leukopenia; P, antiphospholipid antibody; RNP, 
anti-RNP antibody; Sm, anti-Smith antibody; T, thrombocytopenia. 
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Figure 1. IgH and IgL chain sequence features. IgH V and J gene rep-
ertoire, CDR3 length, and number of positively charged residues from new 
emigrant (A) and mature naive (B) B cells. Pie charts depict VH and JH family 
usage (top) and the proportion of IgH CDR3s with 0, 1, 2, or  3 positive 
charges (bottom). Bar graphs show frequencies of IgH CDR3s with 9 aa 
(white bars), 10–14 aa (light gray bars), 15–19 aa (dark gray bars), and  20 
aa (black bars). The absolute number of sequences analyzed in each B cell 
compartment is indicated in the center of the pie charts. V and J family 
gene usage for Ig  and Ig  light chains from new emigrant (C) and mature 
naive (D) B cells. Values for controls in this and other figures were published 
previously and are shown here for comparison (13). p-values indicated 
below the charts are in comparison with control (reference 13). 
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SLE patients are specifically enriched for ANAs, we ana-
lyzed the subcellular staining pattern of these antibodies by
IFA on HEp-2 cell–coated slides (Fig. 2, C and D, and Fig.
S2). We found that, similar to healthy control antibodies,
HEp-2–reactive antibodies from new emigrant B cells of
SLE patients were not enriched in ANAs and only a small
fraction of the self-reactive antibodies expressed by mature
naive B cells from SLE patients recognize nuclear antigens
as measured by IFA (Fig. 2 D). We conclude that in SLE,
HEp-2–reactive antibodies fail to be removed in the pe-
ripheral checkpoint between the new emigrant and mature
naive B cell compartments.
 
High numbers of polyreactive antibodies are present in 
mature naive B cells of patients with SLE
 
In addition to HEp-2 reactivity, we also measured the reac-
tivity of the cloned antibodies to a defined set of antigens in-
cluding ssDNA, dsDNA, insulin, and LPS (Fig. 3). In
healthy individuals, 55% of newly arising human B cells in
the bone marrow express antibodies that bind to at least two
of these antigens and, therefore, are considered polyreactive
(13). However, the majority of these potentially harmful an-
tibodies are removed from the repertoire at the early imma-
ture B cell stage and only a small number of the new emi-
grant B cells that leave the bone marrow are weakly
polyreactive (13). Therefore, we reasoned that increased
numbers of polyreactive antibodies in the peripheral blood
new emigrant B cell fraction of SLE patients would reflect a
failure to remove potentially harmful autoantibodies during
early B cell development in the bone marrow. Of the three
patients tested, only SLE101 showed a significant increase in
polyreactive antibodies in the new emigrant B cell compart-
ment (51.5 vs. 7.4% in control; P 
 
 
 
 0.0001; Fig. 3 A). Many
of these antibodies (5/17) also differed qualitatively from the
control polyreactive antibodies in that they displayed stron-
ger levels of antigen binding in the ELISA (Fig. 3 A). Thus,
Figure 2. HEp-2 ELISA and immunofluorescence. HEp-2 ANA ELISA 
results for antibodies cloned from new emigrant (A) and (B) mature naive 
B cells from SLE patients. Dotted lines show ED38 positive control (refer-
ences 13, 44). Horizontal line shows cut-off OD405 for positive reactivity. 
Staining patterns of antibodies found in new emigrant (C) and mature (D) 
antibodies by IFA (Fig. S2). For each patient, the frequency of HEp-2 reactive 
and nonreactive clones as measured by HEp-2 ANA ELISA (A and B) or IFA 
(C and D) is summarized in pie charts with the number of antibodies 
tested indicated in the centers. All p-values are in comparison to previ-
ously published controls from the same B cell compartment (reference 13). 
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the frequency and strength of reactivity of the polyreactive
antibodies in the new emigrant B cell compartment of
SLE101 is similar to that found in the early immature B cells
in the bone marrow of healthy donors (55.2%; P 
 
 
 
 0.804;
reference 13). SLE100 and SLE122 also showed an increase
in the number of polyreactive antibodies in the new emi-
grant B cell fraction, but this did not reach statistical signifi-
cance (13.9 and 16.7%, respectively, vs. 7.4% in controls;
Fig. 3 A). We conclude that SLE101 shows a significant de-
fect in the early B cell tolerance checkpoint between the
bone marrow and the periphery.
Significantly increased numbers of mature naive B cells
from all three SLE patients expressed self-reactive antibodies
as measured by HEp-2 reactivity (Fig. 2, B and D). To deter-
mine whether mature naive B cells were also enriched in
polyreactive antibodies, we tested antibodies from all three
patients in antigen-specific ELISAs (Fig. 3 B). We found high
frequencies of polyreactive antibodies in the mature naive B
cell compartment of all three patients when compared with
healthy controls (controls: 4.3 vs. 30.8% for SLE100, P 
 
 
 
0.0002; 25.8% for SLE101, P 
 
 
 
 0.004; 24.4% for SLE122,
P 
 
 
 
 0.003; P 
 
  
 
0.0001 for SLE combined; Fig. 3 B), and some
of these antibodies demonstrated high levels of reactivity in
ELISA, a feature that was not seen in mature naive B cells
from healthy donors (Fig. 3 B and reference 13). In the case
of SLE100 and SLE122, the level of polyreactivity in the ma-
ture naive compartment represents an increase when com-
pared with the new emigrant compartment, whereas in
Figure 3. Polyreactivity ELISAs. Antibodies from (A) new emigrant and 
(B) mature naive B cells were tested by ELISA for reactivity with ssDNA, dsDNA, 
insulin, and LPS. Dotted lines show ED38 positive control (references 13, 
44). Horizontal line shows cut-off OD405 for positive reactivity. The frequency 
of reactive clones in percent and the absolute number of reactive antibod-
ies out of all tested antibodies are indicated below the graphs. p-values 
are in comparison to previously published controls from the same B cell 
compartment (reference 13). 
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SLE101, the number of polyreactive clones decreased in the
transition. We conclude that patients with SLE have an ab-
normal peripheral B cell tolerance checkpoint resulting in the
expression of large numbers of self-reactive antibodies in the
mature naive B cell compartment.
 
Phosphatidylserine (PS) reactive antibodies
 
Two of the three SLE patients (SLE100 and SLE101) had in-
creased serum titers of antiphospholipid antibodies, whereas
SLE122 did not (Table I and Supplemental Materials and
methods). To test if the antibodies from naive B cells of
SLE100 and SLE101 included antiphospholipid specificities,
we tested all antibodies from new emigrant and mature B cells
for reactivity against PS (Fig. 4 and Tables S1–S6). We found
that polyreactive antibodies from all three patients were reac-
tive with PS (Fig. 4 and Tables S1–S6). However, this finding
was independent of increased serum autoantibody titers against
PS as measured in SLE101 but not in SLE100 or SLE122 as
part of the serology (Supplemental Materials and methods). We
conclude that polyreactive antibodies enriched in naive B cells
in SLE are also reactive with SLE-associated antigens.
 
DISCUSSION
 
Previous studies of the antibody repertoire expressed by pe-
ripheral B cells in SLE revealed enormous variability be-
tween patients (33). Studies of individual CD19
 
 
 
 cells from
SLE patients showed alterations in mutational activity in IgH
and IgL genes, and alterations of Ig repertoire (28–33). The
diverse nature of Ig repertoire alterations, including bias to-
ward V
 
H
 
3, V
 
H
 
4-34, and V
 
 
 
1 gene family usage, has been
demonstrated by a number of groups (34–38). Our Ig se-
quence analysis is consistent with these findings and, in com-
bination with antigen-binding experiments, also establishes
that the Ig gene repertoire is not predictive of a self-reactive
antibody selection bias in SLE.
For example, V
 
H
 
3 usage was reported to be increased in
SLE (29), and we found this V
 
H
 
 gene family overrepresented
in mature naive B cells in SLE122, but not in the other two
patients. More importantly, we found no correlation between
V
 
H
 
3 and self-reactivity; only V
 
H
 
4 showed a small relative en-
richment in autoreactivity (Fig. S3, available at http://www.
jem.org/cgi/content/full/jem.20042251/DC1). Autoreactiv-
ity and polyreactivity are associated with positively charged
and long heavy chain CDR3s (13, 39–44). Consistent with
this observation, we found a statistically significant correlation
between the number of positive charges in IgH CDR3 and
polyreactivity (Fig. S3). A consistent finding among all three
SLE patients was a significant increase in autoreactive and
polyreactive antibodies in the mature naive B cell compart-
ment. However, neither the number of IgH CDR3-positive
charges nor their lengths or specific Ig gene usage was suffi-
cient to predict polyreactivity in SLE patients or healthy vol-
unteers (reference 13 and Fig. S3). We conclude that the di-
versity of the human antibody repertoire precludes the use of
sequence analysis alone as an indicator of either self-reactivity
or abnormalities in self-reactive B cell selection.
How might the diverse genetic defects associated with
SLE lead to a break in early B cell tolerance checkpoints and
an accumulation of autoreactive B cells in the mature naive
B cell compartment? Experiments in mice indicate that cen-
tral B cell tolerance is mediated by three mechanisms: recep-
tor editing, deletion, and anergy (14–16, 45). B cell receptor
signaling strength and the physical nature of the self-antigen
(soluble vs. membrane bound) are important determinants in
the choice between editing, deletion, and anergy (46, 47). A
number of genes that regulate B cell receptor signaling
thresholds have been implicated in SLE, and any of these
might impact on selection to produce a defect in early im-
mature B cell tolerance (4, 48). A defect in either of these
mechanisms could account for the high number of autoreac-
tive antibodies in new emigrant B cells of SLE101.
In all three SLE patients, we observed a striking increase
in autoreactive antibodies in mature naive B cells, and there is
little known about the mechanisms that govern the tolerance
Figure 4. PS ELISA. Antibodies from (A) new emigrant and (B) mature 
naive B cells were tested by ELISA for reactivity with phosphatidylserine 
(PS). Dotted lines show ED38 positive control (references 13, 44). Horizon-
tal line shows cut-off OD405 for positive reactivity as determined by com-
parison to the negative control antibody mGO53 (green line) and low pos-
itive control antibody eiJB40 (red line) that were included in the assay. The 
frequency of reactive clones in percent and the absolute number of reac-
tive antibodies out of all tested antibodies are indicated below the graphs. 
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checkpoint between new emigrant and mature naive B cell
compartments. Indeed, the roles of positive and negative se-
lection in this transition are still debated (20–23), but B cells
with autoreactive receptors are deleted between the new em-
igrant and mature naive B cell stage in mice (49, 50). Our ex-
periments show that the central and peripheral B cell toler-
ance checkpoints are regulated independently in humans
because the defect in SLE101 was partially corrected in the
transition to the mature naive B cell compartment, whereas it
was exacerbated in SLE100 and SLE122. These differences
are likely to reflect the individual patients genotype and the
relative contributions of SLE susceptibility genes such as sig-
nal transducers, coreceptors, cytokines, and regulators of anti-
gen clearance that govern B cell tolerance checkpoints (4–8).
Do high numbers of autoreactive antibodies in the ma-
ture naive B cell compartment of SLE patients predispose to
the development of the disease and the generation of clinical
symptoms? Individuals that develop SLE have high titers of
circulating autoantibodies long before they develop clinical
symptoms of the disease (51). Although the antiself-antibod-
ies expressed by naive B cells in SLE may not be directly
pathogenic, they can readily be mutated to higher affinity
and switch to downstream isotypes once a B cell is activated
and antinuclear specificities might be selected or expanded
during this maturation process (17, 52–55).
All three SLE patients showed high frequencies of anti-
bodies that recognized DNA, which is part of cellular debris
(56–58). In this context, DNA can trigger B cell responses
by simultaneously activating B cell antigen receptor and Toll
like receptor signaling pathways leading to potent B cell re-
sponses, including antibody production and further B cell
maturation (59, 60). Mutations that interfere with physio-
logic pathways governing antigen clearance would be partic-
ularly likely to induce autoantibody responses in individuals
such as the SLE patients described here because they show
large numbers of polyreactive B cells that would be activated
by DNA containing antigens. In healthy individuals, inhibi-
tory mechanisms such as those mediated by inhibitory recep-
tors, for example Fc
 
 
 
RIIb, may limit activation of the small
numbers of autoreactive B cells present in the mature B cell
compartment (61). We speculate that these protective mech-
anisms are overwhelmed in the presence of large numbers of
mature naive self-reactive B cells that produce polyreactive
antibodies in SLE. Consistent with this idea, transgenic ex-
pression of BAFF in mice produces an SLE-like disease by
increasing the number of autoreactive B cells that survive the
transition between the new emigrant and mature naive B
cell compartment (62–67).
In conclusion, our experiments show that patients with
SLE have a previously unappreciated defect in early B cell
tolerance checkpoints, leading to accumulation of large num-
bers of autoreactive B cells in the mature naive B cell com-
partment. This feature of the disease may explain why SLE
patients suffer frequent relapses after conventional treatment
and suggests that restoring tolerance in mature naive B cells
might be an effective approach to more enduring therapies.
 
MATERIALS AND METHODS
 
Patient samples and single B cell sorting.
 
The study was performed in
accordance with IRB-reviewed protocols of the UT Southwestern Medical
Center (IRB no. 0199-017) and The Rockefeller University (HWA-0518-
1003), and all samples were obtained after signed informed consent. Periph-
eral blood samples from three untreated SLE patients were obtained at the
Division of Pediatric Rheumatology of UT Southwestern Medical Center
and shipped overnight. Peripheral blood from healthy controls was obtained
at The Rockefeller University and kept overnight on a shaker at room tem-
perature. SLE and control blood samples were processed in parallel for com-
parison and FACS settings. Control data shown are from previously pub-
lished healthy controls (13). Single B cell isolation was performed as
described previously (13). In brief, B cells were preenriched by incubation of
peripheral blood with RossetteSep according to the manufacturer’s instruc-
tions (Stem Cell Technologies, Inc.) followed by Ficoll-Hypaque (Amer-
sham Biosciences) gradient centrifugation. Enriched B cells were stained
with anti–human CD10-PE (BD Biosciences) before separation with anti-
PE magnetic bead columns (Miltenyi Biotec). CD10-enriched and CD10-
depleted B cell fractions were stained with anti–human CD19-APC, anti–
human CD10-PE, anti–human IgM-biotin, and anti–human CD27-FITC
antibodies (BD Biosciences), and biotinylated anti–human IgM antibody was
revealed using streptavidin-PeCy7 (Caltag Laboratories). New emigrant B
cells (CD19
 
 
 
CD10
 
 
 
IgM
 
 
 
CD27
 
 
 
) were isolated from the CD10-enriched B
cell fraction and mature naive B cells (CD19
 
 
 
CD10
 
 
 
IgM
 
 
 
CD27
 
 
 
) were
isolated from the CD10-depleted B cell fraction (Fig. S1). Single B cells were
purified by FACS into 96-well plates containing 4 
 
 
 
l of 0.5 
 
 
 
 PBS, 10 mM
DTT, 8 U RNAsin (Promega), and 3 U Prime RNase Inhibitor (Eppen-
dorf) using a FACSvantage (Becton Dickinson). All samples were immedi-
ately frozen on dry ice and stored at 
 
 
 
70
 
 
 
C.
 
PCR amplification and expression vector cloning.
 
Single cell cDNA
was synthesized in the original sort plates in a total volume of 14.5 
 
 
 
l (4 
 
 
 
l
sort lysis solution 
 
 
 
 10.5 
 
 
 
l RT-PCR reaction mix). RT-PCR reaction mix
contained 150 ng random hexamer primer (pd[N]
 
6
 
; Amersham Biosciences),
0.5% vol/vol Igepal CA-630 (NP40; Sigma-Aldrich), 7 mM DTT, 4 U
RNAsin (Promega), 7.5 U Prime RNase Inhibitor (Eppendorf), 1.2 mM
each dNTP, and 50 U Superscript II RT (Invitrogen), and cDNA was syn-
thesized at 42
 
 
 
C for 55 min. Individual IgH (
 
 
 
) and IgL chain 
 
 
 
 or 
 
 
 
 gene
rearrangements were amplified in two successive rounds of PCR (50 cycles
each) before cloning into human Ig
 
 
 
1, Ig
 
 
 
, or Ig
 
 
 
 expression vectors using
primers that include restriction sites as described previously (13). Primer se-
quences were as described in Table S7, available at http://www.jem.org/cgi/
content/full/jem.20042251/DC1. Individual Ig genes were amplified with
3.5 
 
 
 
l cDNA or first PCR product in 40 
 
 
 
l of total reaction volume with 7.5
p.m. 5
 
 
 
 and 3
 
 
 
 primers or primer mixes, 312.5-
 
 
 
M each dNTP and 1 U
Hotstar Taq DNA polymerase (QIAGEN). Ig genes were analyzed using Na-
tional Center for Biotechnology Information IgBLAST.
 
Antibody production and purification.
 
Antibodies were expressed in
vitro as described previously (13). In brief, human embryonic kidney fibro-
blast 293A cells were cotransfected with 12.5 
 
 
 
g/ml of IgH and IgL chain
encoding plasmid DNA by calcium phosphate precipitation. Cells were
washed with serum-free DMEM 8–12 h after transfection and thereafter
cultured in DMEM supplemented with 1% Nutridoma SP (Roche). Super-
natants were collected after 8 d of culture. Antibodies were purified by
binding to protein G–Sepharose (Amersham Biosciences) and elution with
0.1 M glycine buffer, pH 
 
  
 
3. Eluted antibodies were kept at physiologic
pH. Antibody concentrations in supernatants and of purified antibodies
were determined by anti–human IgG1 ELISA using human monoclonal
IgG1 as standard (Sigma-Aldrich).
 
ELISA and IFA. 
 
ELISAs were performed as described previously (13). In
brief, tissue culture supernatants were adjusted to a starting antibody concen-
tration of 1 
 
 
 
g/ml for polyreactivity ELISAs and used at three subsequent
1:4 dilutions in PBS. Specific antigens were coated on microtiter plates (Easy- 
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wash Polystyrene Plates; Costar) at 10 
 
 
 
g/ml for ssDNA, dsDNA, and LPS
(Sigma-Aldrich) or 5 
 
 
 
g/ml for recombinant human insulin (Sigma-
Aldrich). For PS ELISAs, plates were coated with 50 
 
 
 
l 10 
 
 
 
g/ml 
 
L
 
-
 
 
 
-phos-
phatidyl-
 
L
 
-serine, dioleoyl (Sigma-Aldrich) in ethanol and plates were al-
lowed to air dry. Samples from SLE patients were considered negative if the
OD
 
405
 
 did not exceed a threshold value as indicated in each graph at any of
the four dilutions in at least three independent experiments (Tables S1–S6).
Threshold values were set in all assays using antibodies from healthy donors
and included the negative control antibodies mGO13, mGO53, low positive
control antibody eiJB40, and high polyreactive antibody ED38 (13, 44).
HEp-2 ELISAs were performed on QUANTA Lite ANA ELISA plates (IN-
OVA Diagnostics) and coated with HEp-2 cell lysates. Purified antibodies
were used at a concentration of 25 
 
 
 
g/ml with three subsequent 1:4 dilu-
tions in PBS. The threshold OD
 
405
 
 below which samples were considered
negative was 0.3. Positive and negative controls included sera from patients
and healthy individuals (INOVA Diagnostics) as well as ED38 (13) and were
included in every experiment. All ELISAs were developed with horseradish
peroxidase–labeled goat anti–human IgG Fc Ab (Jackson ImmunoResearch
Laboratories) and horseradish peroxidase substrate (Bio-Rad Laboratories).
OD405 was measured on a microplate reader (Molecular Devices).
IFAs were performed as described previously (13). In brief, HEp-2 cell
coated slides (Bion Enterprises, Ltd.) were incubated at room temperature
with purified antibodies at 25–150  g/ml for 30 min, washed in PBS and
visualized with FITC anti–human Ig by fluorescence microscopy. Controls
included ED38 (13) and positive and negative sera (Bion Enterprises, Ltd.
and Fig. S2).
Statistics.  p-values for Ig gene repertoire analyses, analysis of positive
charges in IgH CDR3, and antibody reactivity were calculated by 2   2 or
2   5 Fisher’s Exact test or  2 test. p-values for IgH CDR3 length were
calculated by Student’s t test.
Online supplemental material. Supplemental Materials and methods
describes clinical information for SLE100, SLE101, and SLE122. Tables S1–
S6 show IgH and IgL chain characteristics and antibody reactivities with ds-
DNA, ssDNA, LPS, insulin, and PS from new emigrant and mature naive B
cells of SLE100, SLE101, and SLE122. Table S7 shows PCR primer se-
quences. Fig. S1 shows representative FACS profiles of CD10-enriched and
CD10-depleted B cell fractions used for single cell purification. Fig. S2
shows representative IFA staining patterns of representative nonreactive
SLE antibodies and positive and negative controls. Fig. S3 shows VH usage
and IgH CDR3 length for polyreactive versus nonpolyreactive antibodies
from B cells of SLE patients. Online supplemental material is available at
http://www.jem.org/cgi/content/full/jem.20042251/DC1.
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